Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrike Faust

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Breast Cancer Research and Treatment|May 30, 2015
HBOC multi-gene panel testing: comparison of two sequencing centersChristopher Schroeder, Ulrike Faust, Marc Sturm, et al.
Breast (Edinburgh, Scotland)|May 22, 2025
Clinical genome sequencing in patients with hereditary breast and ovarian cancer: Concept, implementation and benefitsDennis Witt, Marc Sturm, Antje Stäbler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2022
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approachesCristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.
BMC Cancer|August 10, 2019
Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive womenIlnaz Sepahi, Ulrike Faust, Marc Sturm, et al.
European Journal of Human Genetics : EJHG|July 28, 2023
Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patientsChristopher Schroeder, Ulrike Faust, Luisa Krauße, et al.
Journal of the National Cancer Institute|December 29, 2020
Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation CarriersJulika Borde, Corinna Ernst, Barbara Wappenschmidt, et al.
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
Cancer Medicine|March 10, 2018
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian CancerJan Hauke, Judit Horvath, Eva Groß, et al.
Human Molecular Genetics|March 25, 2016
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithmsMiguel de la Hoya, Omar Soukarieh, Irene López-Perolio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2022
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic VariantsShuai Li, Valentina Silvestri, Goska Leslie, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|May 30, 2015
HBOC multi-gene panel testing: comparison of two sequencing centersChristopher Schroeder, Ulrike Faust, Marc Sturm, et al.
Breast (Edinburgh, Scotland)|May 22, 2025
Clinical genome sequencing in patients with hereditary breast and ovarian cancer: Concept, implementation and benefitsDennis Witt, Marc Sturm, Antje Stäbler, et al.
European Journal of Cancer (Oxford, England : 1990)|December 10, 2022
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approachesCristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.
BMC Cancer|August 10, 2019
Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive womenIlnaz Sepahi, Ulrike Faust, Marc Sturm, et al.
European Journal of Human Genetics : EJHG|July 28, 2023
Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patientsChristopher Schroeder, Ulrike Faust, Luisa Krauße, et al.
Journal of the National Cancer Institute|December 29, 2020
Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation CarriersJulika Borde, Corinna Ernst, Barbara Wappenschmidt, et al.
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
Cancer Medicine|March 10, 2018
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian CancerJan Hauke, Judit Horvath, Eva Groß, et al.
Human Molecular Genetics|March 25, 2016
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithmsMiguel de la Hoya, Omar Soukarieh, Irene López-Perolio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2022
Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic VariantsShuai Li, Valentina Silvestri, Goska Leslie, et al.
Pageof 3